Your session is about to expire
← Back to Search
Other
ssNPA Device for Upper Airway Obstruction
N/A
Recruiting
Led By David Zopf, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
All subjects require the presence of at least one symptom of OSA (such as snoring 3 or more nights per week, daytime sleepiness, or hyperactive/inattentive behaviors)
Children with Hypotonic Upper Airway Obstruction (HUAO) including those newly diagnosed with obstructive sleep apnea (OSA) with AHI>10 or AHI>5 with nocturnal hypoxemia (SpO2 nadir <=75%) confirmed by overnight polysomnography
Must not have
Restrictive thoracic disorders
Presence of supraglottic airway collapse or more distal airway stenosis or collapse (for example glottic, subglottic stenosis, or concern for distal airway stenosis or malacia)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 16 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether a new device can help kids with a breathing condition during sleep.
Who is the study for?
This trial is for children with Hypotonic Upper Airway Obstruction and obstructive sleep apnea who've had a tonsillectomy or can't have one. They must show symptoms like snoring, daytime sleepiness, or hyperactivity. Kids with severe breathing issues during sleep, bleeding disorders, certain airway collapses, active COVID-19 infection, or those on blood thinners cannot join.
What is being tested?
The study tests if the Self-Supporting Nasopharyngeal Airway (ssNPA) device helps treat obstructive sleep apnea in kids with muscle hypotonia affecting their upper airways. It's an alternative to traditional treatments post adenotonsillectomy.
What are the potential side effects?
Potential side effects of using ssNPA may include discomfort in the nose and throat area, difficulty tolerating the device during sleep, nasal discharge or bleeding, and possible irritation at the site where the device sits.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I experience symptoms like snoring, daytime sleepiness, or hyperactivity.
Select...
My child has severe sleep apnea or breathing issues at night confirmed by a sleep study.
Select...
I have had my tonsils removed or cannot have them removed due to health reasons.
Select...
My tonsils are not very large.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a lung condition that restricts my breathing.
Select...
I have a blockage or narrowing in my upper airway.
Select...
I have a bleeding disorder.
Select...
I have a moderate to severe weakness of the windpipe.
Select...
I currently have an active COVID-19 infection.
Select...
I need medication to prevent blood clots.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 16 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Apnea-hypopnea index (AHI)
Self-Supporting Nasopharyngeal Airway (ssNPA) tolerance
Secondary study objectives
Daytime sleepiness
Quality of life as indicated by the dimensions of the PedsQL (pediatric quality of life) instrument.
Sleep quality
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Self-Supporting Nasopharyngeal Airway (ssNPA)Experimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention
Waitlist control group: While waiting, participants will continue to receive the treatment they would have had before which will likely include being placed on the waiting list for positive airway pressure (PAP). After a period of being on the waitlist (8 weeks) there is an option to cross-over to the device arm.
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,852 Previous Clinical Trials
6,432,702 Total Patients Enrolled
6 Trials studying Down Syndrome
752 Patients Enrolled for Down Syndrome
National Institutes of Health (NIH)NIH
2,811 Previous Clinical Trials
8,161,218 Total Patients Enrolled
9 Trials studying Down Syndrome
1,777 Patients Enrolled for Down Syndrome
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,929 Previous Clinical Trials
47,765,190 Total Patients Enrolled
10 Trials studying Down Syndrome
1,105 Patients Enrolled for Down Syndrome
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I experience symptoms like snoring, daytime sleepiness, or hyperactivity.I have a lung condition that restricts my breathing.My child has severe sleep apnea or breathing issues at night confirmed by a sleep study.I have a medical condition that makes using a nasal airway support unsuitable.You have a medical or social situation that could make it hard for you to follow the study plan or attend follow-up appointments. Some psychiatric conditions, like ADHD or conduct disorder, won't be excluded, but severe autism will be excluded.Your carbon dioxide levels during sleep are consistently too high.I have a blockage or narrowing in my upper airway.I have a bleeding disorder.I have had my tonsils removed or cannot have them removed due to health reasons.I have a moderate to severe weakness of the windpipe.You have a sleep test result that shows you have a low number of breathing pauses during sleep without low oxygen levels, or very few breathing pauses with low oxygen levels.I currently have an active COVID-19 infection.My tonsils are not very large.I need medication to prevent blood clots.
Research Study Groups:
This trial has the following groups:- Group 1: Standard of Care
- Group 2: Self-Supporting Nasopharyngeal Airway (ssNPA)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger